We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Anavex Life Sciences (AVXL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of AVXL and the rest of the Medical group's stocks.
Anavex Life Sciences is a member of the Medical sector. This group includes 903 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AVXL is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AVXL's full-year earnings has moved 23.81% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that AVXL has returned about 11.58% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 0.39% on average. This shows that Anavex Life Sciences is outperforming its peers so far this year.
Looking more specifically, AVXL belongs to the Medical - Biomedical and Genetics industry, which includes 386 individual stocks and currently sits at #79 in the Zacks Industry Rank. Stocks in this group have lost about 3.39% so far this year, so AVXL is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track AVXL. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Anavex Life Sciences (AVXL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of AVXL and the rest of the Medical group's stocks.
Anavex Life Sciences is a member of the Medical sector. This group includes 903 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AVXL is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AVXL's full-year earnings has moved 23.81% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that AVXL has returned about 11.58% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 0.39% on average. This shows that Anavex Life Sciences is outperforming its peers so far this year.
Looking more specifically, AVXL belongs to the Medical - Biomedical and Genetics industry, which includes 386 individual stocks and currently sits at #79 in the Zacks Industry Rank. Stocks in this group have lost about 3.39% so far this year, so AVXL is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track AVXL. The stock will be looking to continue its solid performance.